Acrux LimitedASX: ACR

Acrux receives $0.55m advance on FY26 R&D Tax Incentive

· Issued by Acrux Limited

Filed with ASX · · 1 page · English

Summary by 6ix AI

This funding will support the development of products and working capital management following FDA confirmation of Acrux’s Hormone Replacement Therapy regulatory pathway. The advance represents a significant portion of the estimated R&D Tax Incentive for a defined four-month period.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Acrux Limited on 6ix

Story so far

Earlier from Acrux

Later from Acrux

All Acrux news releases